Medline Industries is primarily owned by a consortium of large private equity firms—Blackstone, The Carlyle Group, and Hellman & Friedman—alongside a significant minority stake retained by the founding Mills family. The deal that created this ownership structure was a roughly 34 billion dollar leveraged buyout completed in 2021, which turned Medline into one of the largest privately held medical-supply companies in the world.

Current ownership snapshot

  • A private equity consortium led by Blackstone , The Carlyle Group, and Hellman & Friedman holds a majority stake in Medline Industries.
  • The Mills family (the original founders) still owns a substantial minority stake and continues to play a major role in the company’s leadership and strategy.
  • Singapore’s sovereign wealth fund GIC also participated as an investor in the 2021 transaction, adding long-term institutional capital to the structure.

How ownership changed

  • Before 2021, Medline was effectively a family-owned business, controlled by the Mills family for decades after briefly being public in the 1970s.
  • In June 2021, the company agreed to the 34 billion dollar leveraged buyout, one of the largest healthcare private equity deals ever, shifting control to the private equity consortium while keeping the Mills family as the largest single non‑institutional shareholder.

Why this matters now

  • The private equity ownership has been associated with a push for faster growth, international expansion, and potential preparation for a future public listing, including confidential IPO filings reported in late 2024–2025.
  • Medline’s status as a privately held, sponsor‑backed giant in medical supplies means its strategic decisions—pricing, product mix, acquisitions—are strongly influenced by both financial sponsors and the still‑involved founding family.

Information gathered from public data available on the internet and portrayed here.